Clinical trial · Interventional
EPA Supplementation in Cancer Patients Receiving Abdominal Radiotherapy -
N-3 Fatty Acid EPA Supplementation in Cancer Patients Receiving Abdominal Radiotherapy - A Randomised Controlled Trial.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Malnutrition occurs frequently in patients with cancer during and after radiotherapy to the gastrointestinal (GI) area and can lead to negative outcomes. N-3 fatty acids from fish, especially eicosapentaenoic acid (EPA) may possess anticachectic properties. The aim of this study is to investigate the effect of two nutritional interventions; dietary counselling and an oral nutritional supplement (ONS) containing 2.2 g of the n-3 fatty acid EPA (Forticare®) or standard care, including dietary counselling and protein supplementation when needed.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Abdominal Cancer | Malignant Abdominal Neoplasm | ALIAS | 0.90 |
| Energy Supply | — | UNRESOLVED | — |
| Protein Deficiency | — | UNRESOLVED | — |
| Radiotherapy; Complications | — | UNRESOLVED | — |
| Weight Loss | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Fish oil | Dietary Supplement | — | UNRESOLVED |
| standard care | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Fish oil
- description
- dietary counselling including an oral nutritional supplement (ONS) containing 2.2 g of n-3 fatty acid EPA (Forticare®)
- interventionNames
- Dietary Supplement: Fish oil
- type
- PLACEBO_COMPARATOR
- label
- standard care
- description
- The departmental usual procedure with the possibility of requiring of a dietician when needed
- interventionNames
- Other: standard care
Primary outcomes (1)
- measure
- Change in weight (%)
- timeFrame
- 6 weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * referred to radiotherapy for dissminated, abdominal cancer * \> 18 years of age * able to understand and comply with the intervention * willingness to participate after oral and written conscent Exclusion Criteria: * conditions precluding evaluations of end-points * dementia * operations planned in the observation period
References
Publications (1)
- DERIVEDPatursson P, Moller G, Muhic A, Andersen JR. N-3 fatty acid EPA supplementation in cancer patients receiving abdominal radiotherapy - A randomised controlled trial. Clin Nutr ESPEN. 2021 Jun;43:130-136. doi: 10.1016/j.clnesp.2021.03.001. Epub 2021 Mar 16. PMID 34024504